Home|Journals|Articles by Year|Audio Abstracts
 

Review Article

J App Pharm Sci. 2023; 13(11): 16-23


Updates on the roles of epigenetics in the mechanism, diagnosis, and treatment of triple-negative breast cancer: A review

Eko Fuji Ariyanto, Abdan Syakura Danil, Rima Destya Triatin, Salsabila Ariefani.




Abstract
Cited by 0 Articles

Triple-negative breast cancer (TNBC) is a very aggressive and diverse kind of breast cancer. Drugs that target the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are less effective against TNBC because it lacks steroid hormone receptors. Recent research has shown that the pathogenesis of TNBC is also associated with epigenetic markers that either activate or silence genes, including DNA methylation, histone remodeling, and noncoding RNA-mediated regulation. Therefore, TNBC patients may benefit therapeutically from epigenetic reprogramming to return these genes to their natural state of expression. Here, we elaborate on the epigenetic alterations linked to the etiology of TNBC and potential treatment options. By reversing the identified epigenetic modifications, the function of the affected genes may be restored, hence improving the treatment response.

Key words: breast cancer; DNA methylation; epigenetics; histone modification; non-coding RNA






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.